<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">jofin</journal-id><journal-title-group><journal-title xml:lang="ru">Журнал инфектологии</journal-title><trans-title-group xml:lang="en"><trans-title>Journal Infectology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-6732</issn><publisher><publisher-name>IPO “АIDSSPbR"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.22625/2072-6732-2018-10-1-47-54</article-id><article-id custom-type="elpub" pub-id-type="custom">jofin-694</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>ОЦЕНКА КОНЦЕНТРАЦИИ РАСТВОРИМОГО РЕЦЕПТОРА CD14 В ПЛАЗМЕ У ВИЧ-ИНФИЦИРОВАННЫХ ПОТРЕБИТЕЛЕЙ ОПИАТОВ</article-title><trans-title-group xml:lang="en"><trans-title>LEVELS OF PLASMA SOLUBLE CD14 IN HIV-INFECTED OPIATE USERS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Холодная</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Kholodnaya</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>ассистент</p><p>кафедра инфекционных болезней и эпидемиологии</p><p>тел.: 8(812)338-70-58</p></bio><email xlink:type="simple">ancold@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лиознов</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lioznov</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>заведующий кафедрой</p><p>кафедра инфекционных болезней и эпидемиологии </p><p>заместитель директора по научной работе</p><p>д.м.н.</p><p>тел.: 8(812)338-70-58</p></bio><email xlink:type="simple">dlioznov@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Блохина</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Blokhina</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., заместитель директора, ведущий научный сотрудник</p><p>лаборатория клинической фармакологии аддиктивных состояний</p><p>отдел психофармакологии</p><p>Институт фармакологии им. А.В. Вальдмана </p><p>тел.: 8(812) 338-60-73</p></bio><email xlink:type="simple">blokhinaelena@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ярославцева</surname><given-names>Т. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Yaroslavtseva</surname><given-names>T. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>ученый секретарь</p><p>Институт фармакологии им. А.В. Вальдмана </p><p>тел.: 8(812)338-60-73</p></bio><email xlink:type="simple">tatianayaroslavtseva@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Крупицкий</surname><given-names>Е. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Krupitskiy</surname><given-names>E. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>заместитель директора по научной работе, руководитель</p><p>отдел наркологии</p><p>д.м.н., профессор;</p><p>тел.: 8(812)365-22-17</p></bio><email xlink:type="simple">kruenator@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>First Saint-Petersburg State Medical University named after academician I.P. Pavlov</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова; &#13;
Научно-исследовательский институт гриппа</institution><country>Россия</country></aff><aff xml:lang="en"><institution>First Saint-Petersburg State Medical University named after academician I.P. Pavlov; &#13;
Research Institute of Influenza</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center of Psychiatry and Neurology named after V.M. Bekhterev</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>02</day><month>04</month><year>2018</year></pub-date><volume>10</volume><issue>1</issue><fpage>47</fpage><lpage>54</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Холодная А.Н., Лиознов Д.А., Блохина Е.А., Ярославцева Т.С., Крупицкий Е.М., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Холодная А.Н., Лиознов Д.А., Блохина Е.А., Ярославцева Т.С., Крупицкий Е.М.</copyright-holder><copyright-holder xml:lang="en">Kholodnaya A.N., Lioznov D.A., Blokhina E.A., Yaroslavtseva T.S., Krupitskiy E.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.niidi.ru/jofin/article/view/694">https://journal.niidi.ru/jofin/article/view/694</self-uri><abstract><p>Хроническая активация иммунной системы является одним из основных факторов патогенеза ВИЧ-инфекции. Значительная роль в хронической иммунной активации принадлежит транслокации бактериальных компонентов из кишечника в кровоток, в первую очередь липополисахарида (ЛПС) клеточной стенки грамотрицательных микроорганизмов. Растворимая форма рецептора CD14 (sCD14) является маркером моноцитарной активации, индуцированной ЛПС. Гипотеза исследования: у больных ВИЧ-инфекцией потребление опиатов способствует усилению микробной транслокации из кишечника, проявляющейся более высокой концентрацией sCD14 в плазме крови.</p><sec><title>Цель исследования</title><p>Цель исследования: оценить влияние употребления опиатов на концентрацию sCD14 в плазме крови у больных ВИЧ-инфекцией.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы: у 351 больного ВИЧ-инфекцией определена концентрация растворимого рецептора CD14 в плазме в трёх временных точках: при включении в исследование, через 12 и 24 мес. Сопоставлены значения концентрации sCD14 в группах: 1) активных потребителей опиатов; 2) наркопотребителей, отрицающих употребление опиатов за последние 30 дней; 3) пациентов, отрицающих факт употребления опиатов в анамнезе.</p></sec><sec><title>Результаты</title><p>Результаты: у активных опиатных наркопотребителей выявлено значимо более высокое среднее значение концентрации sCD14 в плазме крови (2213±596 нг/мл) в сравнении с пациентами, не употреблявшими опиаты за последние 30 дней (1930±597 нг/мл), и лицами, отрицающими употребление опиатов (1915±577 нг/мл) (р&lt;0,001).</p></sec><sec><title>Заключение</title><p>Заключение: полученные результаты указывают, что у больных ВИЧ-инфекцией употребление опиатов приводит к усилению ЛПС-индуцированной моноцитарной активации, что, в свою очередь, свидетельствует о более интенсивной транслокации бактериальных компонентов.</p></sec></abstract><trans-abstract xml:lang="en"><p>Chronic immune activation is one of the main causes of HIV disease progression. Bacterial components passed to the bloodstream from the gut as a result of microbial translocation, are known to induce immune activation. Component of Gram-negative bacteria’s cell walls, the lipopolysaccharide (LPS), is considered to be the major marker of microbial translocation. Through the activation of myeloid cells (predominantly monocytes) LPS causes the secretion of soluble CD14, thus making it a marker of LPS bioactivity. Besides sCD14 was shown to correlate with immune status in HIVinfected patients and to be an independent predictor of disease progression.</p><sec><title>Hypothesis</title><p>Hypothesis: opiates increase microbial translocation from the gut in HIV-infected patients that is manifested by a higher concentration of sCD14 in plasma.</p></sec><sec><title>Aim</title><p>Aim: to estimate the influence of opiate use on the level of sCD14 in plasma of HIV-infected patients.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. Longitudinal study of 351 HIV positive individuals. Concentration of sCD14, was evaluated at 3 time points: baseline, after 12 and 24 months. Following groups were studied: 1) current opiate users – opiate use within past 30 days; 2) opiate users, who denied consumption of opiates within past 30 days; 3) people claiming to never have used opiates.</p></sec><sec><title>Results</title><p>Results. In dynamic assessment sCD14 mean was significantly higher in current opiate users (2222,46±39,02 ng/ml) against patients who denied opiates within past 30 days (1930±597 ng/ml) and those, claiming to never have used opiates (1915±577 ng/ml) (p&lt;0,001).</p></sec><sec><title>Conclusion</title><p>Conclusion. Opiate use in the course of HIV disease leads to increase in LPS induced monocyte activation which therefore signifies more intensive microbial translocation.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ВИЧ-инфекция</kwd><kwd>микробная транслокация</kwd><kwd>sCD14</kwd><kwd>потребители инъекционных наркотиков</kwd><kwd>опиаты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>HIV</kwd><kwd>microbial translocation</kwd><kwd>sCD14</kwd><kwd>drug users</kwd><kwd>opiates</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Brenchley, J.M. Microbial translocation is a cause of systemic immune activation in chronic HIV/ J.M. Brenchley [et al.] // Nat. Med. – 2006. – V. 12. – P.1365 – 1371.</mixed-citation><mixed-citation xml:lang="en">Brenchley JM et al. Microbial translocation is a cause of systemic immune activation in chronic HIV. Nat. Med. 2006;12:1365-1371.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Marchetti, G. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count / G. Marchetti [et al.] // AIDS. – 2011. V. 25 (11). – P. 1385–1394.</mixed-citation><mixed-citation xml:lang="en">Marchetti G et al. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count . AIDS. 2011; 25(11):1385-94.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Klatt, N.R. Microbial translocation, immune activation and HIV disease / N.R. Klatt [et al.] // Trends Microbiol. – 2013. – V. 21(1). – P. 6–13.</mixed-citation><mixed-citation xml:lang="en">Klatt NR et al. Microbial translocation, immune activation and HIV disease . Trends Microbiol. 2013; 21(1): 6-13.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Nowroozalizadeh, S. Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections / S. Nowroozalizadeh [et al.] // J Infect Dis. – 2010. — V. 201(8). – P.1150–1154.</mixed-citation><mixed-citation xml:lang="en">Nowroozalizadeh S. Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections. J Infect Dis. 2010; 201(8):1150–1154.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Brenchley, J.M. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract / J.M. Brenchley [et al.] // J. Exp. Med. – 2004. – V. 200(6). – P. 749–759.</mixed-citation><mixed-citation xml:lang="en">Brenchley JM et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 2004; 200(6):749-759.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Epple, H.J. Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients / H.J. Epple [et al.] // Gut. – 2009. – V. 58. – P. 220–227.</mixed-citation><mixed-citation xml:lang="en">Epple HJ et al. Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIVinfected patients .Gut. 2009; 58:220–227.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Dillon, S.M. An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia / S.M. Dillon [et al.] // Mucosal Immunol. – 2014. – V.7. – P. 983–994.</mixed-citation><mixed-citation xml:lang="en">Dillon SM et al. An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol. 2014; 7:983–994.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Meng, J. Morphine induces bacterial translocation in mice by compromising intestinal barrier function in a TLRDependent manner / J. Meng [et al.] // PLoS ONE. – 2013. – V. 8(1). – e54040. DOI: 10.1371.</mixed-citation><mixed-citation xml:lang="en">Meng J, Yu H, Ma J, Wang J, Banerjee S, Charboneau R et al. Morphine induces bacterial translocation in mice by compromising intestinal barrier function in a TLR-Dependent manner. PLoS ONE. 2013; 8:e54040.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Babrowski, T. Pseudomonas aeruginosa virulence expression is directly activated by morphine and is capable of causing lethal gut-derived sepsis in mice during chronic morphine administration / T. Babrowski [et al.] // Ann. Surg. – 2012. – V.255(2). – P.386–393.</mixed-citation><mixed-citation xml:lang="en">Babrowski T, Holbrook C, Moss J, Gottlieb L, Valuckaite V, Zaborin A et al. Pseudomonas aeruginosa virulence expression is directly activated by morphine and is capable of causing lethal gut-derived sepsis in mice during chronic morphine administration. Ann. Surg. 2012; 255: 386–393.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Hilburger, M. E. Morphine induces sepsis in mice / M. E. Hilburger [et al.] // J. Infect. Dis. – 1997. – V.176. – P.183–188.</mixed-citation><mixed-citation xml:lang="en">Hilburger ME, Adler MW, Truant AL, Meissler JJ, Satishchandran V, Rogers T J, et al. Morphine induces sepsis in mice. J. Infect. Dis. 1997; 176: 183–188.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Sindberg, G. M. An infectious murine model for studying the systemic effects of opioids on early HIV pathogenesis in the gut / G. Sindberg [et al.] // J. Neuroimmune Pharmacol. – 2014. – V.10. – P.74–87.</mixed-citation><mixed-citation xml:lang="en">Sindberg GM, Sharma U, Banerjee S, Anand V, Dutta R, Gu CJ, et al. An infectious murine model for studying the systemic effects of opioids on early HIV pathogenesis in the gut. J. Neuroimmune Pharmacol. 2014; 10: 74–87.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Donahoe, R.M. Opiates as potential cofactors in progression of HIV-1 infections to AIDS / R.M. Donahoe [et al.] // J. Neuroimmunol. – 1998. – V.83. – P. 77–87.</mixed-citation><mixed-citation xml:lang="en">Donahoe RM, Vlahov D. Opiates as potential cofactors in progression of HIV-1 infections to AIDS. J Neuroimmunol. 1998;83(1-2):77-87.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Noel, R.J. Opiates, immune system, acquired immunodeficiency syndrome, and nonhuman primate model / R.J. Noel [et al.] // Journal of neurovirology. – 2008. – V. 14(4). – P. 279–285.</mixed-citation><mixed-citation xml:lang="en">Richard J, Noel Jr, et al. Opiates, immune system, acquired immunodeficiency syndrome, and nonhuman primate model. J Neurovirol. 2008; 14(4): 279–285.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Krastinova, E. High Soluble CD14 Levels at Primary HIV-1 Infection Predict More Rapid Disease Progression / E. Krastinova [et al.] // The Journal of Infectious Diseases. – 2015. – V. 212. – P.909–913.</mixed-citation><mixed-citation xml:lang="en">Krastinova E, Lecuroux C, Leroy C, Seng R, Cabie A et al. High Soluble CD14 Levels at Primary HIV-1 Infection Predict More Rapid Disease Progression. The Journal of Infectious Diseases. 2015; 212(6): 909–913.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Sandler, N.G. Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection/ N.G. Sandler [et al.] // The Journal of Infectious Diseases. – 2011. – V.203(6). – P. 780–790.</mixed-citation><mixed-citation xml:lang="en">Sandler NG, Wand H, Roque A, et al. Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection. The Journal of Infectious Diseases. 2011;203(6):780-790.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Karris, M.Y. Predictors of virologic response in persons who start antiretroviral therapy during recent HIV infection / M.Y. Karris [et.al] // AIDS. – 2014. – V.28(6). – P.841–849.</mixed-citation><mixed-citation xml:lang="en">Karris MY, Kao Y, Patel D, et al. Predictors of virologic response in persons who start antiretroviral therapy during recent HIV infection. AIDS (London, England). 2014;28(6):841-849.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Хасанова, Г.Р. Микробная транслокация и системный воспалительный ответ при ВИЧ-инфекции / Г.Р. Хасанова [и др.] // Саратовский научно-медицинский журнал. – 2013. – Т. 9, № 3. – С. 508–512.</mixed-citation><mixed-citation xml:lang="en">Khasanova GR, Bikkinina OI, Anokhin VA. Mikrobnaya translokatsiya i sistemnyy vospalitel’nyy otvet pri VIChinfektsii. Saratovskiy nauchno-meditsinskiy zhurnal. 2013; 9(3): 508–512 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ancuta, P. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients / P. Ancuta [et. al] // PLoS ONE. – 2008. – V.3. – e2516.</mixed-citation><mixed-citation xml:lang="en">Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS ONE. 2008; 3:e2516.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
